|
Market Closed -
TEL AVIV STOCK EXCHANGE
11:47:02 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 2,443.00 ILa | +0.33% |
|
+2.99% | +8.10% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
Company Valuation: Kamada Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,410 | - | - |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | 8.15% | - | - |
| Enterprise Value (EV) | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,410 | 1,410 | 1,410 |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | 8.15% | 0% | 0% |
| P/E | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.7x | 1.31x | 2.51x | 2.17x | 2.35x | 2.32x | 2.06x | 1.89x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.32x | 2.06x | 1.89x |
| EV / EBITDA | - | - | 0x | 0x | 0x | 9.28x | 7.13x | 6.67x |
| EV / EBIT | -0x | 0x | 0x | 0x | 0x | 13.9x | 11.1x | 9.83x |
| EV / FCF | -0x | - | -0x | 0x | 0x | 23.9x | 15.8x | 11.6x |
| FCF Yield | -4.52% | - | -0.43% | 10.5% | 3.73% | 4.18% | 6.32% | 8.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 340.3 | 469.1 | 510.9 | 586.9 | 555.7 | 608.5 | 685.4 | 745.7 |
| EBITDA 1 | - | - | 86.36 | 124.5 | 129.3 | 151.9 | 197.9 | 211.5 |
| EBIT 1 | -2.286 | 16.44 | 36.08 | 73.11 | 80.79 | 101.2 | 127.5 | 143.5 |
| Net income 1 | -7.323 | -8.417 | 29.7 | 52.73 | 62.2 | 83.39 | 101.3 | 113.4 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 20.55 | 13.72 | 22.27 | 22.11 | 22.60 | 24.43 | 24.43 | 24.43 |
| Nbr of stocks (in thousands) | 44,786 | 44,826 | 57,476 | 57,492 | 57,682 | 57,710 | - | - |
| Announcement Date | 15/03/22 | 15/03/23 | 06/03/24 | 05/03/25 | 11/03/26 | - | - | - |
1ILS in Million2
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 453M | |
| 35.8x | 12.9x | 27.02x | 0.55% | 1,116B | |
| 37.07x | 6.25x | 17.38x | 2.11% | 610B | |
| 36.17x | 8.31x | 17.13x | 2.45% | 501B | |
| 112.15x | 5.92x | 25.35x | 2.35% | 358B | |
| 20.49x | 5x | 12.4x | 2.64% | 366B | |
| 21.24x | 5.55x | 13.66x | 2.88% | 288B | |
| 22x | 4.43x | 12.71x | 1.99% | 261B | |
| 27.56x | 7.08x | 12.68x | 2.32% | 235B | |
| -45.98x | 7.04x | 27.26x | 2.1% | 195B | |
| Average | 29.61x | 6.94x | 18.40x | 2.15% | 393.02B | |
| Weighted average by Cap. | 35.04x | 8.17x | 19.98x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KMDA Stock
- Valuation Kamada Ltd.
Select your edition
All financial news and data tailored to specific country editions
